“Until now, healthcare systems have evaluated the quality of medical care based solely on whether errors were made. But that isn’t good enough. A lack of errors doesn’t mean a patient had a good outcome or benefited from the treatment,” says Yannik Schreckenberger, co-founder and CEO of heartbeat medical.
heartbeat’s software empowers doctors to practice personalized, data-driven medicine that puts a patient’s needs first. The software seamlessly integrates the collections of Patient Reported Outcomes (PROs) into a clinical setting. Following a treatment, heartbeat automatically follows up with a patient at regular intervals and asks them how they are doing. The data that is collected conforms with recognized international reporting standards. This makes it easy for doctors to compare their patients’ outcomes with thousands of established data sets. In this way, patients’ quality of life can become the new benchmark in healthcare.
Heartbeat is already used by many European hospitals, including the Charité, Europe’s leading university hospital, as well as the Sana and Helios clinics, Germany’s largest private hospital chains. In total, more than 50,000 patients have already benefited from heartbeat’s analysis.
With the investment of HV Holtzbrinck Ventures, heartbeat medical can further expand its data analysis. “We will optimize our processes and give our customers even better access to important treatment data. At the end of the day, patients will benefit the most, as physicians will be able to make personalized, data-driven decisions faster in the future,” says Yannik Schreckenberger.
“The founders and the product immediately won us over. Today, hospitals and doctors are paid only for the services provided. The patient’s quality of life does not affect compensation”, says Felix Klühr, Investment Manager at HV Holtzbrinck Ventures. “heartbeat medical can change the system – for the benefit of patients, doctors and providers. Numerous well-known customers already speak for the success of the founders Yannik Schreckenberger, Sebastian Tilch, Marc Tiedemann and Yunus Uyargil.”